RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
E-Therapeutics Stock

E-Therapeutics Employees 2024

E-Therapeutics Employees

18

Ticker

ETX.L

ISIN

GB00B2823H99

WKN

A0M8VQ

In 2024, E-Therapeutics employed 18 people, a 0% change from the 18 number of employees in the previous year.

E-Therapeutics Aktienanalyse

What does E-Therapeutics do?

E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It was founded in 2003 by Prof. Malcolm Young and has made significant progress in the field of drug development since then. The company has always aimed for an innovative business model focused on identifying new compounds through computer simulations. E-Therapeutics has developed a unique platform called Network Pharmacology, which simulates complex biological systems and identifies potential drug candidates. The platform uses mathematical models and artificial intelligence to identify molecules that can have a positive effect on specific cells. E-Therapeutics' business model is designed to collaborate with partners in developing new drug candidates. The company offers its platform and expertise to support customers in identifying new chemical compounds. E-Therapeutics works closely with top pharmaceutical companies to advance the development of new drugs. E-Therapeutics is divided into three divisions, each focusing on different areas of medical drug research: 1. Oncology division: This division focuses on developing drugs for the treatment of cancer. E-Therapeutics uses its unique platform to develop targeted therapies tailored to the individual needs of the patient. The platform can also be used to identify new biomarkers and potential therapeutics for a variety of cancer diseases. 2. Neurology division: E-Therapeutics' neurology division focuses on identifying drugs for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and Huntington's. E-Therapeutics' platform has already been used to identify new drug candidates that could have a positive effect on the symptoms of these diseases. 3. Infectious Diseases division: E-Therapeutics' infectious diseases division focuses on the development of drugs for the treatment of infectious diseases such as HIV and influenza. E-Therapeutics uses its platform to identify new compounds that have the potential to fight infections and prevent the spread of diseases. E-Therapeutics has a pipeline of products targeting different medical fields. One promising product is ETS-101, a novel drug candidate for the treatment of pain. ETS-101 has already shown positive results in preclinical studies and is currently in phase 1 studies. Another promising product is ETS-6103, being developed for the treatment of depression. ETS-6103 has been successfully tested in preclinical studies and is currently in phase 2 clinical development. In summary, E-Therapeutics focuses on developing drugs that work at a biological level. The company's innovative business model, unique platform, and collaboration with top pharmaceutical companies make it a key player in medical drug research. With a pipeline of promising products, E-Therapeutics has the potential to change the face of medical drug research and advance the world of medicine. Answer: E-Therapeutics PLC is an English biotechnology company that develops medical compounds using innovative technologies. It focuses on identifying new compounds through computer simulations and has developed a unique platform called Network Pharmacology. The company collaborates with partners to develop new drug candidates and is divided into divisions focused on oncology, neurology, and infectious diseases. E-Therapeutics has a pipeline of promising products, including ETS-101 for pain treatment and ETS-6103 for depression treatment. It aims to advance medical drug research and contribute to the field of medicine. E-Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining E-Therapeutics's Employee Base

E-Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding E-Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing E-Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

E-Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in E-Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about E-Therapeutics stock

How many employees does E-Therapeutics have this year?

E-Therapeutics has 18 undefined employees this year.

How many employees did E-Therapeutics have compared to the previous year?

Compared to the previous year, E-Therapeutics had 0% more employees.

What impact did the number of employees have on the company E-Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of E-Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of E-Therapeutics?

The number of employees can also have an impact on investors of E-Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of E-Therapeutics affect the company?

An increase in equity of E-Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in E-Therapeutics's equity affect the company?

A reduction in equity of E-Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of E-Therapeutics?

Some factors that can influence the equity of E-Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of E-Therapeutics so important for investors?

The equity of E-Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at E-Therapeutics influence the company?

The number of employees at E-Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at E-Therapeutics evolved in recent years?

In recent years, the number of employees at E-Therapeutics has changed by 0.

How many employees does E-Therapeutics currently have?

E-Therapeutics currently has 18 undefined employees.

Why is the number of employees important for investors of E-Therapeutics?

The number of employees is important for investors of E-Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can E-Therapeutics take to change the number of employees?

To change the number of employees, E-Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does E-Therapeutics pay?

Over the past 12 months, E-Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, E-Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of E-Therapeutics?

The current dividend yield of E-Therapeutics is .

When does E-Therapeutics pay dividends?

E-Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of E-Therapeutics?

E-Therapeutics paid dividends every year for the past 0 years.

What is the dividend of E-Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is E-Therapeutics located?

E-Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von E-Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of E-Therapeutics from 11/19/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did E-Therapeutics pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of E-Therapeutics in the year 2023?

In the year 2023, E-Therapeutics distributed 0 GBP as dividends.

In which currency does E-Therapeutics pay out the dividend?

The dividends of E-Therapeutics are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von E-Therapeutics

Our stock analysis for E-Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of E-Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.